Delivering immunotherapy to the heart of lung cancer
- Researcher: Professor Kairbaan Hodivala-Dilke
- Institution: Queen Mary University of London, England
- Award Amount: £208,131 for 3 years from 1st April 2019
- Cancer Type: Lung Cancer
Professor Kairbaan Hodivala-Dilke has previously found that by using low doses of a drug originally designed to cut off the blood supply to a tumour, they are, counterintuitively, able to increase blood flow to the tumour and increase the level of chemotherapy that reaches the tumour. This odd finding has led Professor Hodivala-Dilke to investigate if a similar approach could be used to target the cancer-killing effects of immunotherapy directly at the tumour.
Professor Hodivala-Dilke and her team, based at Queen Mary University of London, England, aim to test a new drug in pre-clinical studies to see if it can boost the effects of immunotherapy in NSCLC. If successful, her team hopes that they will be able to take the new drug forward into clinical trials to treat lung cancer patients.
The Research That Is Happening Right Now
Explore current projects to see how far-reaching our research is from a global perspective.
See the difference our research projects make.